Alpha Teknova, Inc. ( TKNO ) NASDAQ Global Market

Cena: 4.74 ( 5.92% )

Aktualizacja 08-22 21:58
NASDAQ Global Market
Branża: Drug Manufacturers - Specialty & Generic
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Alpha Teknova, Inc. zapewnia krytyczne odczynniki dla rynku nauk przyrodniczych w Stanach Zjednoczonych i na arenie międzynarodowej. Jego odczynniki umożliwiają odkrycie, rozwój i produkcję produktów biofarmaceutycznych, takich jak terapie leków, nowe szczepionki i diagnostyka molekularna. Firma oferuje wstępnie pobudzone płyty medialne do wzrostu komórek i klonowania; Płynne pożywki i suplementy do ekspansji komórkowej; oraz odczynniki biologii molekularnej do manipulacji próbką, ponownego zawieszania i oczyszczania. Obsługuje rynek nauk przyrodniczych, w tym firmy farmaceutyczne i biotechnologiczne, organizacje rozwoju kontraktów i produkcji, franczyzy diagnostyczne in vitro oraz akademickie i rządowe instytucje badawcze. Firma została założona w 1996 roku i ma siedzibę w Hollister w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 210
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 25.3174
Ilość akcji: Brak danych
Debiut giełdowy: 2021-06-25
WWW: https://www.teknova.com
CEO: Mr. Stephen Gunstream
Adres: 2290 Bert Drive
Siedziba: 95023 Hollister
ISIN: US02080L1026
Wskaźniki finansowe
Kapitalizacja (USD) 253 929 624
Aktywa: 124 099 000
Cena: 4.74
Wskaźnik Altman Z-Score: 5.5
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -12.2
Ilość akcji w obrocie: 25%
Średni wolumen: 305 019
Ilość akcji 53 515 200
Wskaźniki finansowe
Przychody TTM 36 347 000
Zobowiązania: 36 831 000
Przedział 52 tyg.: 4.0 - 10.37
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.4
P/E branży: 22.5
Beta: 0.359
Raport okresowy: 2025-11-06
WWW: https://www.teknova.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Stephen Gunstream President, Chief Executive Officer & Director 937 786 1979
Mr. Matthew C. Lowell Chief Financial Officer 593 782 1971
Mr. Damon A. Terrill General Counsel, Chief Compliance Officer & Secretary 215 775 1971
Ms. Jennifer Henry Senior Vice President of Marketing 0 0
Lista ETF z ekspozycją na akcje Alpha Teknova, Inc.
Symbol ETF Ilość akcji Wartość
VTI 336 258 1 651 026
IWM 266 507 1 204 613
IWO 94 053 425 121
IBB 71 943 325 180
VTWO 55 159 270 830
2B70.DE 37 040 146 459
BTEK.L 37 040 126 717
BTEC.L 37 040 167 420
BTEE.L 37 040 167 420
IWC 26 005 117 544
ZPRR.DE 19 588 83 021
R2SC.L 19 588 71 842
R2US.L 19 588 94 805
XRSG.L 12 409 4 250 501
XRSU.L 12 409 56 090
XRS2.DE 12 409 49 118
VTWG 9 088 44 622
TINY 5 591 25 271
RSSL 5 401 24 412
BIB 1 969 8 899
IBBQ 1 899 9 191
XSU.TO 1 790 11 953
UWM 1 098 4 962
URTY 907 4 099
DFAC 141 637
HDG 13 58
SBIO.MI 0 62 039
RTYS.L 0 4 625
SBIO.L 0 70 805
SC0K.DE 0 4 052
Wiadomości dla Alpha Teknova, Inc.
Tytuł Treść Źródło Aktualizacja Link
Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Larew - William Blair Chad Wiatrowski - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2025 Financial Results Conference Call. seekingalpha.com 2025-05-10 18:50:33 Czytaj oryginał (ang.)
Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™  cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million globenewswire.com 2025-05-08 20:01:00 Czytaj oryginał (ang.)
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. globenewswire.com 2025-04-24 23:51:00 Czytaj oryginał (ang.)
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. globenewswire.com 2025-03-19 10:00:00 Czytaj oryginał (ang.)
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System globenewswire.com 2025-03-11 21:00:00 Czytaj oryginał (ang.)
Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2024 Earnings Call March 4, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Matthew Parisi - KeyBanc Capital Markets Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jennifer Henry, Senior Vice President of Marketing. seekingalpha.com 2025-03-05 01:20:17 Czytaj oryginał (ang.)
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue guidance of $39-42 million globenewswire.com 2025-03-04 18:05:00 Czytaj oryginał (ang.)
Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. globenewswire.com 2025-02-20 18:05:00 Czytaj oryginał (ang.)
Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode. seekingalpha.com 2024-11-09 07:17:43 Czytaj oryginał (ang.)
Teknova Reports Third Quarter 2024 Financial Results Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue guidance of $35-38 million globenewswire.com 2024-11-07 18:01:00 Czytaj oryginał (ang.)
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024 HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. globenewswire.com 2024-10-24 20:01:00 Czytaj oryginał (ang.)
What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now? Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2024-10-22 17:06:12 Czytaj oryginał (ang.)
Alpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Jennifer Henry - SVP, Marketing Stephen Gunstream - President & CEO Matt Lowell - CFO Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cowen Paul Knight - KeyBanc Matt Larew - William Blair Operator Good day and thank you for standing by. Welcome to the Teknova's Second Quarter 2024 Financial Results. seekingalpha.com 2024-08-14 00:46:05 Czytaj oryginał (ang.)
Teknova Reports Second Quarter 2024 Financial Results Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million globenewswire.com 2024-08-13 20:01:00 Czytaj oryginał (ang.)
Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024 HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. globenewswire.com 2024-07-30 20:01:00 Czytaj oryginał (ang.)
Recent Insider Buying Is Focused on These 5 Stocks 24/7 Insights With the new quarter begun and second-quarter earnings reports starting to come in, insider buying has slowed to a trickle. 247wallst.com 2024-07-21 13:15:17 Czytaj oryginał (ang.)
Teknova Announces Closing of $15.4 Million Private Placement HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024. globenewswire.com 2024-07-12 20:25:00 Czytaj oryginał (ang.)
Teknova Announces $15.4 Million Private Placement HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024. globenewswire.com 2024-07-12 05:00:00 Czytaj oryginał (ang.)
Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second quarter ended June 30, 2024. globenewswire.com 2024-07-09 21:00:00 Czytaj oryginał (ang.)
After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO) Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com 2024-06-24 14:35:21 Czytaj oryginał (ang.)
Alpha Teknova (TKNO) Upgraded to Buy: What Does It Mean for the Stock? Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-06-06 17:01:16 Czytaj oryginał (ang.)
Alpha Teknova, Inc. (TKNO) Q1 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President and Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Steven Mah - TD Cowen Matt Larew - William Blair Vidyun Bais - BTIG Operator Good day and thank you for standing by. Welcome to Teknova's First Quarter 2024 Financial Results Conference Call. seekingalpha.com 2024-05-17 14:55:05 Czytaj oryginał (ang.)
Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-Tek™  Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million globenewswire.com 2024-05-13 20:01:00 Czytaj oryginał (ang.)
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times globenewswire.com 2024-05-07 14:00:00 Czytaj oryginał (ang.)
Teknova to Report First Quarter 2024 Financial Results on May 13, 2024 HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market. globenewswire.com 2024-04-29 20:01:00 Czytaj oryginał (ang.)
Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Alpha Teknova (TKNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2024-04-24 14:36:09 Czytaj oryginał (ang.)
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-38 million globenewswire.com 2024-03-11 18:01:00 Czytaj oryginał (ang.)
Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market. globenewswire.com 2024-02-21 18:01:00 Czytaj oryginał (ang.)